FeesSafety
Pluang+

Getty Realty trades at a discount with strong Q3 results and growth potential from recent acquisitions.

Analyst Insights
23 Oct 2026
Seeking Alpha
View Source
Bullish
Getty Realty trades at a discount with strong Q3 results and growth potential from recent acquisitions.

Getty Realty Corp. remains a strong buy as it trades significantly below its intrinsic value despite solid fundamentals. The company reported a 99.7% occupancy rate, strong tenant rent coverage, and a 14% increase in adjusted funds from operations (AFFO) in Q3, supporting a sustainable 7.28% dividend yield. Recent acquisitions and investments totaling over $760 million at attractive yields highlight Getty's growth potential, backed by strong liquidity and no near-term debt maturities. Conservative valuation estimates suggest the market undervalues the stock, indicating upside potential for investors.

Getty Realty provides context for real estate investors. For readers following US real estate stocks, here is Pluang's market snapshot as of Oct 23, 2026 16:11 WIB: Out of 47 priced real estate stocks, 28 rose and 16 fell. Notable movers include AMT at USD 191.80 with a 5.63% increase and 100% buy order activity, AIV at USD 1.69 up 3.05%, and UDR at USD 35.99 down 0.53% with 100% buy order activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
15 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App